Key opinion leaders presented critical updates and insights on onco-urological issues at #UROonco24 last month. We have compiled a report featuring several key lectures, and a selection of #PCa,#BCa and #RCC webcast presentations for you to watch. 👇 meeting.uroonco.uroweb.org/uroonco24-repo…

Patients with small recurrent low-grade Ta tumours can be effectively and safely offered office fulguration. #NMIBC #BladderCancer #EAUguidelines uroweb.org/guidelines/non…

What’s new in the European Association of Urology (EAU) #EAUGuidelines on prostate cancer?!? GU Cast has read all 239 pages so you don’t have to! Plus we have Guideline Vice-Chair Derya Tilki, MD and Board Member Gianluca Giannarini plus Elio Mazzone to discuss four hot topics youtu.be/qls8-1ShdB8?si…

Online now: #ArtificialIntelligence for detection of #ProstateCancer in biopsies during active surveillance Anders Bjartell doi.org/10.1111/bju.16…

What are Dr. Giancarlo Marra’s insights regarding the comparison between long- & short-course ADT in the RADICALS-HD randomised trial? Read his expert commentary on the UROONCO PCa article of the month. 👇 prostate.uroonco.uroweb.org/publication/du… #ProstateCancer

Only 1 week left to register for #EMUC24 with special rates! Enjoy up to 60% off when you sign up before 1 August (23:59 CEST). Secure your place at the congress now. 👉 emuc.org/how-to-registe… ESMO - Eur. Oncology ESTRO

This 🆕 #EAUguidelines Cheat Sheet on #urolithiasis covers various aspects, including the unclear progression of small, asymptomatic calculi, conservative treatment, pharmacological options for uric acid stones, and indications for stone removal. Download uroweb.org/guidelines/uro…

Abstract submission is now open for the 40th Annual EAU Congress! EAU25 will be held in Madrid, Spain on 21-24 March 2025 and you could be presenting your research there. Find out more and be sure to submit before 1 November. eaucongress.uroweb.org/scientific-pro…

Do you want to know more about biochemical recurrence in #prostatecancer? Discover key insights and essential guidelines in our latest #UrologyCheatSheet! Thanks to J&J Innovative Medicine España for making this resource possible. Stay informed! ROC Clinic

Expect essential updates and innovative strategies for partial nephrectomy from Alberto Breda, Ben Challacombe, Ruben De Groote, Andrea Minervini, & Alex Mottrie in this latest #UROwebinar. Register here and claim your CME credit upon participation 👇 webinars.uroweb.org/EAU/webinars/1…

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

Increase your understanding of managing adverse events and toxicity in mPCa treatment. Join us in the upcoming new #UROwebinar led by experts Giorgio Gandaglia & Álvaro Pinto. Register now 👇 webinars.uroweb.org/EAU/webinars/1…

Spotlight: Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis by Roy, Fervaha, Spratt, Sun et al. Read the full article here: europeanurology.com/article/S0302-… #UroSoMe #MedTwitter #Spotlights

📰 Findings from a recent systematic review & network meta-analysis have emphasised the critical role of gender in determining the outcomes of immunotherapy & ADCs in #RCC treatment. Read the RCC Article of the Month, with commentary from Dr. 𝙍𝙞𝙘𝙘𝙖𝙧𝙙𝙤 𝘽𝙚𝙧𝙩𝙤𝙡𝙤 MD PhD kidney.uroonco.uroweb.org/publication/ef…

📹 In this interview from #UROonco24 in Budapest, Dr. Gianluca Giannarini talks with Prof. Geert De Meerleer about the QoL for mPCa patients undergoing treatment. Their conversation features the role & safety of radiation therapy in patients with de novo mPCa.👇 prostate.uroonco.uroweb.org/video/quality-…

Just in 2 weeks!!!! 😬 Another game changer? 🍿🍿🍿🍿🍿 Can't wait to see the outcomes from NIAGARA trial combining chemo and durvalumab as neoadjuvant treatment of MIBC... and also awaiting for data dissection.... Tom Powles Petros Grivas ESMO - Eur. Oncology OncoAlert

🚨 Breaking News from Europe! 🚨 💫🌟European Commission Approves Astellas’ PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer🌟💫 OncoAlert World Bladder Cancer Patient Coalition Bladder Cancer Bladder Cancer Advocacy Network 🔹

📹 In this video interview from #UROonco24 in Budapest, Dr. Elena Castro shares her expert opinion with Dr. Gianluca Giannarini on the challenges of managing treatment-related toxicity & QoL for PCa patients, particularly hormone-sensitive patients. 👇 prostate.uroonco.uroweb.org/video/the-role…

📹 In this exclusive interview from UROonco24, Dr. Juan Gómez Rivas and Dr. Ursula Vogl discuss advancements in genomic profiling and the use of PARP inhibitors in treating mPCa, with a focus on genomic profiling, patient selection and toxicity management. 👇 prostate.uroonco.uroweb.org/video/genomics…

In patients with high-risk localised prostate cancer undergoing a lymph node dissection, you should perform an extended PLND. #ProstateCancer #EAUguidelines uroweb.org/guidelines/pro…